BERKELEY HEIGHTS, NJ - October 2, 2008
- Genta Incorporated (OTCBB: GNTA) announced that the Company will
host a conference call and live audio webcast of its 2008 Annual
Meeting of Shareholders. The meeting will be held on Monday,
October 6, 2008 at 11:00 a.m., EDT at the Company's headquarters
located at 200 Connell Drive, Berkeley Heights, NJ
07922. The presentation will include an overview of the
Company's key programs and strategies by senior management.
Conference call and webcast information:
US/Canada call: 877-634-8606; conference code Genta Annual
Shareholder Meeting
International call: 706-679-3140; conference code Genta Annual
Shareholder Meeting
Audio Webcast:
http://www.genta.com/investorrelation/events.html
Audio replay will be available approximately two hours after the
completion of the call, and will be archived for 30 days. Access
numbers for this replay are: (800) 642-1687 (U.S./Canada) and (706)
645-9291 (International); conference ID number is: 64394129.
Shareholders wishing to attend the meeting may obtain directions by
visiting the Genta website at
http://www.genta.com//
.
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with
cancer. Two major programs anchor the Company's research
platform: DNA/
Genta Announces Webcast of 2008 Annual Shareholders
Meeting
RNA-based Medicines and Small Molecules.
Genasense®
(oblimersen sodium) Injection is the Company's lead compound from
its DNA/RNA Medicines program. Genta is currently recruiting
patients to the
AGENDA
Trial
, a global Phase 3 trial of Genasense in patients with advanced
melanoma. The leading drug in Genta's Small Molecule program
is
Ganite®
(gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with
cancer-related hypercalcemia that is resistant to hydration.
The Company has developed G4544, an oral formulation of the active
ingredient in Ganite, that has recently entered clinical trials as
a potential treatment for diseases associated with accelerated bone
loss. The Company is also developing
tesetaxel
, a novel, orally absorbed, semi-synthetic taxane that is in the
same class of drug as paclitaxel and docetaxel. Ganite and
Genasense are available on a "named-patient" basis in countries
outside the United States. For more information about Genta,
please visit our website at:
http://www.genta.com//
.
SAFE HARBOR
This press release may contain forward-looking statements with
respect to business conducted by Genta Incorporated. By their
nature, forward-looking statements and forecasts involve risks and
uncertainties because they relate to events and depend on
circumstances that will occur in the future. Forward-looking
statements include, without limitation, statements about:
- the Company's ability to obtain necessary regulatory approval
for Genasense® from the U.S. Food and Drug Administration ("FDA")
or European Medicines Agency ("EMEA");
- the safety and efficacy of the Company's products or product
candidates;
- the Company's assessment of its clinical trials;
- the commencement and completion of clinical trials;
- the Company's ability to develop, manufacture, license and
sell its products or product candidates;
- the Company's ability to enter into and successfully execute
license and collaborative agreements, if any;
- the adequacy of the Company's capital resources and cash flow
projections, the Company's ability to obtain sufficient financing
to maintain the Company's planned operations, or the Company's
risk of bankruptcy if it is unsuccessful in obtaining such
financing or in securing shareholder approval to increase the
number of shares authorized for issuance under the Company's
certificate of incorporation, as required by the transactional
documents in our recent financing;
- the adequacy of the Company's patents and proprietary
rights;
- the impact of litigation that has been brought against the
Company and its officers and directors and any proposed
settlement of such litigation; and
- the other risks described under Certain Risks and
Uncertainties Related to the Company's Business, as contained in
the Company's Annual Report on Form 10-K and Quarterly Report on
Form 10-Q.
The Company does not undertake to update any forward-looking
statements. There are a number of factors that could cause
actual results and developments to differ materially. For a
discussion of those risks and uncertainties, please see the
Company's Annual Report on Form 10-K for 2007 and its most recent
quarterly report on Form 10-Q.
SOURCE: Genta Incorporated
CONTACT:
Genta Investor Relations
info@genta.com
